Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ALSUntangled #65: glucocorticoid corticosteroids.
Goslinga JA, Terrelonge M Jr, Bedlack R, Barkhaus P, Barnes B, Bertorini T, Bromberg M, Carter G, Chen A, Crayle J, Dimachkie M, Jiang L, Levitsky G, Lund I, Martin S, Mcdermott C, Pattee G, Pierce K, Ratner D, Slachtova L, Sun Y, Wicks P. Goslinga JA, et al. Among authors: dimachkie m. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3-4):351-357. doi: 10.1080/21678421.2022.2099746. Epub 2022 Aug 23. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 35997522 Review.
ALS Untangled No. 20: the Deanna protocol.
ALSUntangled Group; Fournier C, Bedlack B, Hardiman O, Heiman-Patterson T, Gutmann L, Bromberg M, Ostrow L, Carter G, Kabashi E, Bertorini T, Mozaffar T, Andersen P, Dietz J, Gamez J, Dimachkie M, Wang Y, Wicks P, Heywood J, Novella S, Rowland LP, Pioro E, Kinsley L, Mitchell K, Glass J, Sathornsumetee S, Kwiecinski H, Baker J, Atassi N, Forshew D, Ravits J, Conwit R, Jackson C, Sherman A, Dalton K, Tindall K, Gonzalez G, Robertson J, Phillips L, Benatar M, Sorenson E, Shoesmith C, Nash S, Maragakis N, Moore D, Caress J, Boylan K, Armon C, Grosso M, Gerecke B, Wymer J, Oskarsson B, Bowser R, Drory V, Shefner J, Lechtzin N, Leitner M, Miller R, Mitsumoto H, Levine T, Russell J, Sharma K, Saperstein D, McClusky L, MacGowan D, Licht J, Verma A, Strong M, Lomen-Hoerth C, Tandan R, Rivner M, Kolb S, Polak M, Rudnicki S, Kittrell P, Quereshi M, Sachs G, Pattee G, Weiss M, Kissel J, Goldstein J, Rothstein J, Pastula D, Gleb L, Ogino M, Rosenfeld J, Carmi E, Oster C, Barkhaus P, Valor E. ALSUntangled Group, et al. Among authors: dimachkie m. Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):319-23. doi: 10.3109/21678421.2013.788405. Epub 2013 May 2. Amyotroph Lateral Scler Frontotemporal Degener. 2013. PMID: 23638638 Review. No abstract available.
A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.
Macchi Z, Wang Y, Moore D, Katz J, Saperstein D, Walk D, Simpson E, Genge A, Bertorini T, Fernandes JA, Swenson A, Elman L, Dimachkie M, Herbelin L, Miller J, Lu J, Wilkins H, Swerdlow RH, Statland J, Barohn R; Western ALS (WALS) Rasagiline Study Group. Macchi Z, et al. Among authors: dimachkie m. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):345-52. doi: 10.3109/21678421.2015.1026826. Epub 2015 Apr 2. Amyotroph Lateral Scler Frontotemporal Degener. 2015. PMID: 25832828 Free PMC article.
ALSUntangled No. 29: MitoQ.
ALSUntangled Group. ALSUntangled Group. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):427-9. doi: 10.3109/21678421.2015.1050897. Epub 2015 Jun 19. Amyotroph Lateral Scler Frontotemporal Degener. 2015. PMID: 26090901 No abstract available.
Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis.
Babu S, Macklin EA, Jackson KE, Simpson E, Mahoney K, Yu H, Walker J, Simmons Z, David WS, Barkhaus PE, Simionescu L, Dimachkie MM, Pestronk A, Salameh JS, Weiss MD, Brooks BR, Schoenfeld D, Shefner J, Aggarwal S, Cudkowicz ME, Atassi N. Babu S, et al. Among authors: dimachkie mm. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):15-23. doi: 10.1080/21678421.2019.1672750. Epub 2019 Oct 14. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 31608711 Clinical Trial.
ALSUntangled #67: rituximab.
Li X, Armon C, Barkhaus P, Barnes B, Benatar M, Bertorini T, Bromberg M, Carter GT, Crayle J, Cudkowicz M, Dimachkie M, Feldman EL, Glass J, Goslinga J, Heiman-Patterson T, Jhooty S, Lichtenstein R, Lund I, Mcdermott C, Pattee G, Pierce K, Ratner D, Salmon K, Wicks P, Bedlack R. Li X, et al. Among authors: dimachkie m. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):544-547. doi: 10.1080/21678421.2022.2122845. Epub 2022 Sep 15. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36106861 Review.
ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.
Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study Group. Mitsumoto H, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):192-203. doi: 10.3109/21678421.2013.864312. Epub 2014 Feb 24. Amyotroph Lateral Scler Frontotemporal Degener. 2014. PMID: 24564738 Free PMC article.
Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.
Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A; Phase 2 Trial NP001 Investigators. Miller RG, et al. Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e100. doi: 10.1212/NXI.0000000000000100. eCollection 2015 Jun. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 25884010 Free PMC article.
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH Jr, Distad JB, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, Cudkowicz ME; Mexiletine ALS Study Group. Weiss MD, et al. Neurology. 2016 Apr 19;86(16):1474-81. doi: 10.1212/WNL.0000000000002507. Epub 2016 Feb 24. Neurology. 2016. PMID: 26911633 Free PMC article. Clinical Trial.
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ; Zilucoplan MG Study Group; Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF Jr, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M. Howard JF Jr, et al. Among authors: dimachkie m. JAMA Neurol. 2020 May 1;77(5):582-592. doi: 10.1001/jamaneurol.2019.5125. JAMA Neurol. 2020. PMID: 32065623 Free PMC article. Clinical Trial.
249 results